Approval · Notice of Compliance 37696 · 2026
ZEPBOUND: Notice of Compliance 37696
Issued June 11, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37696
- Date
- June 11, 2026
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of new indication: for once-weekly administration as an adjunct to a reduced-calorie diet and increased physical activity: to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity (BMI 30kg/m2 or greater).. Update to the Product Monograph with new safety information. Update to package insert
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZEPBOUND | Not yet assigned | — |
Medicinal ingredients
- TIRZEPATIDE 2.5 MG per 0.6ML
- TIRZEPATIDE 5 MG per 0.6ML
- TIRZEPATIDE 7.5 MG per 0.6ML
- TIRZEPATIDE 10 MG per 0.6ML
- TIRZEPATIDE 12.5 MG per 0.6ML
- TIRZEPATIDE 15 MG per 0.6ML